News >

Expert Highlights Developments in Myeloid Malignancies

Caroline Seymour
Published: Tuesday, Feb 27, 2018

Suman Kambhampati, MD

Suman Kambhampati, MD
Myelodysplastic syndromes (MDS), precursors to acute myeloid leukemia (AML), are underdiagnosed, according to Suman Kambhampati, MD.

 on Hematologic Malignancies, Kambhampati, co-medical director of the Blood Cancer Program at Sarah Cannon Cancer Institute, detailed available treatments for MDS and ongoing clinical trials investigating targeted treatments in myeloid malignancies.

OncLive: Please provide an overview of the treatment landscape of MDS.

Kambhampati: The 2 main features in MDS are low blood counts and the risk of transforming into AML; those are the 2 broad areas of therapeutic focus. When it comes to low blood counts, we primarily deal with anemia, thrombocytopenia, low platelets, and risk for infections due to low neutrophil counts. MDS is categorized into low- and high-risk disease. Low-risk MDS is often characterized by low blood counts, and the focus in that category is mostly improving blood counts and giving growth factors to stimulate blood production.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication